HomeXLO • NASDAQ
Xilio Therapeutics Inc
Follow
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 16.54M | -29.70% |
Net income | -17.20M | 24.04% |
Net profit margin | — | — |
Earnings per share | -0.62 | 25.30% |
EBITDA | -16.10M | 30.10% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 33.98M | -63.57% |
Total assets | 82.61M | -25.91% |
Total liabilities | 56.84M | 112.80% |
Total equity | 25.76M | — |
Shares outstanding | 36.91M | — |
Price to book | 1.43 | — |
Return on assets | -57.61% | — |
Return on capital | -98.31% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -17.20M | 24.04% |
Cash from operations | -10.50M | 58.41% |
Cash from investing | — | — |
Cash from financing | 954.00K | 156.52% |
Net change in cash | -9.55M | 64.78% |
Free cash flow | -22.75M | -31.82% |
Previous close
$1.07
Day range
$1.03 - $1.12
Year range
$0.49 - $3.25
Market cap
38.76M USD
Avg Volume
239.70K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2016
Headquarters
Website
Employees
73